Us Bancorp \De\ Candel Therapeutics, Inc. Transaction History
Us Bancorp \De\
- $74.1 Billion
- Q1 2025
A detailed history of Us Bancorp \De\ transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 416 shares of CADL stock, worth $2,034. This represents 0.0% of its overall portfolio holdings.
Number of Shares
416Holding current value
$2,034% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CADL
# of Institutions
78Shares Held
15.6MCall Options Held
977KPut Options Held
521K-
Baker Bros. Advisors LP New York, NY2.98MShares$14.6 Million0.29% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.94MShares$9.48 Million9.1% of portfolio
-
Northpond Ventures, LLC1.94MShares$9.46 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.74MShares$8.49 Million0.0% of portfolio
-
Braidwell LP Stamford, CT1.6MShares$7.82 Million0.78% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $141M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...